ERBB2 and breast carcinoma: For HER2 overexpressing breast cancers, the basal-like subtype was associated with the worst outcome, whereas the prognoses of HER2-enriched subtype and luminal B subtype were intertwined, and molecular profiling provided little prognostic value (Figure S5A).